AK112 with chemotherapy vs standard care for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced colorectal cancer that cannot be removed by surgery or has spread to other organs.
- Your tumor has a specific marker called MSS or pMMR.
- You have already received one first treatment that included oxaliplatin, and either it stopped working, you could not tolerate it, or your cancer returned within 6 months after completing that treatment.
- You are between 18 and 75 years old.
- You are in reasonably good health (able to care for yourself) and your major organs (like kidneys, liver, and bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
This trial tests a new combination of drugs (Ivosidenib/AK112, CapeOX chemotherapy, and radiation) for people with advanced colorectal cancer that has spread and cannot be removed with surgery. It is for those whose tumors are MSS (microsatellite stable) type and who have not received recent chemotherapy.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.